09:01 EST Alkermes (ALKS) down 14% at $29.00 after Vibrance-2 Phase 2 alixorexton study data
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes’ Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating
- Alkermes says ‘positive’ results from Vibrance-2 Phase 2 study of alixorexton
- DraftKings downgraded, Instacart upgraded: Wall Street’s top analyst calls
- Alkermes initiated with a Buy at Truist
- RBC says Centessa data highlights ‘impressive profile’ of Alkermes’ alixorexton